Oral supplementation of myoinositol: effects on peripheral nerve function in human diabetics and on the concentration in plasma, erythrocytes, urine and muscle tissue in human diabetics and normals.
28 young diabetics with short disease duration participated in a double-blind study by taking 6 g of myoinositol or placebo daily for 2 months. The aim was to demonstrate a possible beneficial effect of this compound on subclinical diabetic neuropathy. Measurement of vibratory perception threshold, motor and sensory conduction velocity and amplitude of nerve potential did not disclose any effect of the myoinositol given. In accordance with this, no indication for a lack of myoinositol in human diabetic blood or tissue could be found. The concentration of myoinositol in the plasma and erythrocyte of 4 human diabetics was normal or high, even though the loss of urinary myoinositol was greater than in the case of 4 normals. Further, an analysis of the content of free and lipid-bound myoinositol in muscle biopsies taken from the 4 diabetics did not give any indication of deficiency. The content of myoinositol in their muscle tissue remained uninfluenced by oral supplementation of myoinositol.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D004912:Erythrocytes / Q000032:analysis*; D006801:Humans; D007294:Inositol / Q000008:administration & dosage* / Q000032:analysis / Q000097:blood / Q000627:therapeutic use / Q000652:urine; D009132:Muscles / Q000032:analysis*; D010525:Peripheral Nerves / Q000187:drug effects*
D007294:Inositol